Cure8 research brief
This preclinical study identifies a parasite-derived fluid that reduced inflammation, oxidative stress, and microbiome disruption in a mouse model of ulcerative colitis and in intestinal cells, pointing to possible new biological pathways for protecting the gut barrier.
Researchers, clinicians, and investigators interested in IBD mechanisms, microbiome research, and preclinical therapeutic development.
The research used dextran sulfate sodium (DSS) to induce acute colitis in mice and treated them with hydatid cyst fluid (EgHCF).
Treated animals had less weight loss, less colon shortening, improved colon tissue appearance on histology, preserved barrier integrity, lower markers of inflammation and oxidative stress, activation of the Keap1/Nrf2 antioxidant pathway, and shifts in gut microbiota diversity and composition.
Cell-culture experiments with human NCM460 intestinal epithelial cells showed reduced inflammatory marker expression and reactive oxygen species after EgHCF exposure. The study also performed metabolomics and highlighted tryptophan metabolism as associated with the treatment effect in mice.
The work is presented as preclinical mechanistic research (animal and cell models), not a clinical trial or human treatment study.
Findings are from animal and cell experiments; they do not indicate a tested or safe human treatment. The paper focuses on mechanisms (Keap1/Nrf2 pathway, microbiota changes, tryptophan metabolism) rather than clinical outcomes.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Natural Science Foundation of China, award 32503131; award 32503131; Natural Science Foundation of Xinjiang Uygur Autonomous Region, China, award 2024D01C311; Special Funds for Talents of Xinjiang Medical University, award 0103010211; award 0103010211
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD might be interested because the study explores a new natural-product intervention that appears to reduce colitis severity in an animal model by activating the Nrf2 antioxidant pathway — a pathway already...
This study describes a new plant-derived nanoparticle (EBDEVs) that reduced inflammation and improved colon health in a mouse model of ulcerative colitis and altered the gut microbiota — early evidence that may guide...
The study identifies a specific gut microbe and a bile-acid metabolite that reduced inflammation in a mouse colitis model and implicates STAT3/NF-κB pathways — a potential new avenue for microbiome-based therapeutics for...
